JHJinju Han

Jinju Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jinju Han has a total of 151 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Platform-dependent performance of P2A and IRES linkers in multicistronic gene expression

    by Mingyu Ju, Jinju Han

    Background: Efficient co-expression of multiple genes within individual cells is essential for advances in biotechnology and clinical applications. While 2 A peptides and internal ribosome entry sites (IRESs) are widely used linkers, their performance in synthetic mRNA systems—particularly with modified nucleotides—is insufficiently characterized compared to DNA-based platforms. Objective: We systematically compared bicistronic gene expression mediated by ribosome skipping peptide P2A and four viral IRES types across plasmid DNA and synthetic mRNA platforms. Methods: Plasmids were engineered with two open reading frames linked by P2A or four distinct IRES types. mRNAs were generated via in vitro transcription with or without N1-methylpseudouridine (m 1 Ψ) substitution. Expression efficiency was quantified through dual-luciferase assays, using firefly luciferase as a control. Results: We observed distinct linker-dependent expression patterns between DNA and RNA platforms. P2A generally provided superior overall protein expression in both plasmid DNA and m 1 Ψ –modified mRNA systems, with the exception of unmodified mRNA, in which P2A and the poliovirus (PV; type I) IRES produced comparable downstream gene expression. Full substitution of uridine with m 1 Ψ markedly impaired protein expression driven by all IRES. Notably, even partial m 1 Ψ (25%) was sufficient to disrupt type I IRES activity, whereas P2A constructs displayed a gradual increase in protein output with increasing levels of modification. These results indicate that nucleotide modifications fundamentally alter linker performance. Conclusions: Our study highlights the importance of linker-dependent effects in the design of RNA-based expression systems, providing insights for optimizing multi-gene expression strategies. These findings may contribute to the development of next-generation mRNA-based therapeutics, including vaccines.

  • Open Access

    Exploration of Novel Biomarkers Through a Precision Medicine Approach Using Multi‐Omics and Brain Organoids in Patients With Atypical Depression and Psychotic Symptoms

    by Insook Ahn, Soyeon Chang, Jiyoung Lee, Seok‐Ho Choi, Jinju Han, Yangsik Kim

    Major depressive disorder (MDD) with atypical features accompanied by psychotic symptoms represents a severe and under‐researched subtype of depression and severe mental illness, characterized by significant personal and social impact. This study aims to explore novel biomarkers through a precision medicine approach by combining clinical data, white blood cell (WBC) single‐cell RNA sequencing (scRNA‐seq), plasma proteomics, and brain organoid models to uncover immunological and neurological alterations in patients with this condition. Patients exhibited elevated stress, anxiety, depression, and increased WBC counts, although the difference in WBC count is not significant after adjusting for age. Plasma proteomic profiling identified an upregulation of proteins implicated in synaptic formation, including Doublecortin‐Like Kinase 3 (DCLK3) and Calcyon (CALY), as well as immune‐related proteins such as Complement Component 5 (C5). WBC scRNA‐seq revealed significant neutrophil and monocyte transcriptomic alterations, suggesting increased inflammation and immune dysregulation. Patient‐derived brain organoids display reduced growth and distinct gene expression patterns compared to controls, particularly under dexamethasone‐induced stress conditions. Combining WBC scRNA‐seq, plasma proteomics, and brain organoid models offers a novel framework for understanding the pathophysiology of psychiatric disorders, which is one of the most complex disorders.


  • Open Access

    AGO1 in neural progenitor cells orchestrates brain development and sociability via LIN28A-REELIN axis

    by Hyunsu Do, Dayeon Kim, Roberto Jappelli, Hyeokjun Yang, Yiseon Jeon, Geurim Son, Mingyu Ju, Jihoon Son, Insook Ahn, Christina K Lim, et al.

    AGO1, an essential RNA binding protein (RBP) in RNA interference, is associated with autism spectrum disorder (ASD). However, the precise functions of AGO1 in brain development and related disorders remain largely unexplored. Here, we report the critical roles of AGO1 in neural progenitor cells (NPCs) in promoting sociability and shaping the structure of the developing brain. Ago1 knockout (KO) in the mouse brain leads to hyposociability, a characteristic symptom of ASD. In human forebrain organoids, AGO1 KO disrupts the formation of ventricle-like structures and delays cortical layer development. We discovered that AGO1 KO results in a loss of polarity in NPCs, which subsequently reduces neuronal development. These AGO1 KO phenotypes originate from the failure to suppress LIN28A in NPCs. AGO1 is primarily localized in the nucleus within NPCs and binds to the LIN28A promoter region, thereby inhibiting LIN28A transcription. We found that increased LIN28A in AGO1 KO NPCs reduces REELIN expression, a key regulator of brain development, by binding directly to the REELIN mRNA. The aberrant polarity phenotype in AGO1 KO NPCs was successfully ameliorated by either LIN28A knockdown or recombinant REELIN treatment. Collectively, our findings elucidate the intricate molecular mechanisms orchestrated by nuclear AGO1 in NPCs and underscores its pivotal roles in brain development, providing significant insights into ASD.

  • Open Access

    Differential effects of lithium on metabolic dysfunctions in astrocytes derived from bipolar disorder patients

    by Gyu Hyeon Baek, Dayeon Kim, Geurim Son, Hyunsu Do, Gyu-Bum Yeon, Mahn Jae Lee, Moongi Ji, Ji-Hoon Son, Mingyu Ju, Insook Ahn, et al.

    Metabolic alterations have been observed in the brains of patients with bipolar disorder (BD), a neuropsychiatric disorder characterized by alternating episodes of mania and depression. However, the specific contributions of glial cells to these metabolic changes remain largely unknown. Here, we investigate the metabolic characteristics of induced astrocytes (iAstrocytes) derived from induced pluripotent stem cells of BD patients—classified by lithium responsiveness—and healthy controls. Transcriptomic analyses revealed dysregulated expression of genes associated with metabolic diseases in BD iAstrocytes. Compared to control iAstrocytes, BD iAstrocytes showed decreased mitochondrial respiration, increased glycolysis, and elevated lactate secretion, indicating impaired mitochondrial function. These defects were further supported by downregulation of oxidative phosphorylation complex proteins and decreased reactive oxygen species levels. Notably, BD iAstrocytes showed substantial lipid droplet (LD) accumulation, potentially as a consequence of disrupted metabolic homeostasis. Lithium treatment reduced LD levels in lithium-responsive (Li-R) iAstrocytes but failed to restore mitochondrial respiration or normalize lactate secretion. In co-culture with human neurons, lithium-nonresponsive (Li-NR) iAstrocytes exhibited enhanced uptake of neuron-derived lipids and selectively increased neuronal excitability. Metabolomic profiling revealed distinct metabolite signatures between Li-R and Li-NR iAstrocytes, suggesting lithium responsiveness as a key axis of metabolic heterogeneity. Together, our findings identify astrocyte-specific metabolic dysfunction as a hallmark of BD and reveal divergent roles of Li-R and Li-NR iAstrocytes in modulating neuronal function. LD accumulation in Li-NR iAstrocytes may serve as a functional readout for drug screening to identify alternative treatments for patients unresponsive to lithium.


  • Open Access

    Exploration of Novel Biomarkers through a Precision Medicine Approach Using Multi-omics and Brain Organoids in Patients with Atypical Depression and Psychotic Symptoms

    by Insook Ahn, Soyeon Chang, Seok-Ho Choi, Jinju Han, Yangsik Kim

    Major depressive disorder (MDD) with atypical features accompanied by psychotic symptoms represents a severe and under-researched subtype of depression and severe mental illness, characterized by significant personal and social impact. This study aims to explore novel biomarkers through a precision medicine approach by integrating clinical data, white blood cell (WBC) single-cell RNA sequencing (scRNA-seq), plasma proteomics, and brain organoid models to uncover immunological and neurological alterations in patients with this condition. Patients exhibited elevated stress, anxiety, and depression levels, with increased WBC counts. Plasma proteomic profiling identified an upregulation of proteins implicated in synaptic formation, including Doublecortin-Like Kinase 3 (DCLK3) and Calcyon (CALY), as well as immune-related proteins such as Complement Component 5 (C5). WBC scRNA-seq revealed significant neutrophil and monocyte transcriptomic alterations, suggesting increased inflammation and immune dysregulation. Patient-derived brain organoids display reduced growth and distinct gene expression patterns compared to controls, particularly under dexamethasone-induced stress conditions. Integrating multi-omics data and brain organoid models offers a novel framework for understanding the pathophysiology of psychiatric disorder, which is one of the most complex disorders.

  • Open Access

    Developmental deficits, synapse and dendritic abnormalities in a Clcn4 KO autism mice model: endophenotypic target for ASD

    by Seong Mi Lee, Yura Choi, Dayeon Kim, Ha Jin Jeong, Young Ho Do, Sohee Jung, Bomee Lee, Hyung Jun Choi, Suhyeon Kim, Jung-Min Oh, et al.

    Autism spectrum disorder (ASD) is linked to ion channel dysfunction, including chloride voltage-gated channel-4 (CLCN4). We generated Clcn4 knockout (KO) mice by deleting exon 5 of chromosome 7 in the C57BL/6 mice. Clcn4 KO exhibited reduced social interaction and increased repetitive behaviors assessed using three-chamber and marble burying tests. Surprisingly, these symptoms were improved by Risperidone treatment, a drug commonly used to treat ASD. RNA sequencing data from mouse neural progenitor cells (mNPCs) showed that the genes regulating trans-synaptic signaling, transmembrane transport, and neuronal projection development were significantly decreased in Clcn4 knockdown (KD) cells compared to wild type (WT). Moreover, Risperidone treatment increased the genes related to the ion transmembrane transport, membrane potential, and neuron projection development in Clcn4 KD. Abnormalities in synaptic plasticity and dendritic spine formation were also observed in Clcn4 KO compared to WT. We observed that phosphorylation of SYNAPSIN, PSD95, ERK and CREB, as well as the expression of CDK5, were reduced in the brains of Clcn4 KO mice. In Clcn4 KO cortical neurons, the phosphorylation of SYNAPSIN and PSD95 expressions also decreased compared to WT, indicating disrupted synaptic function. Additionally, Sholl analysis revealed a reduction in dendritic branching and neuronal projection length in both mouse and human CLCN4 KD neurons. Finally, the decreased phosphorylation of SYNAPSIN and expression of PSD95 along with dendrite abnormalities were restored after Risperidone treatment. These data suggest that dendritic outgrowth and synapse remodeling may serve as endophenotypic targets for drug efficacy in ASD.


  • Open Access

    miR-124 coordinates metabolic regulators acting at early stages of human neurogenesis

    by Geurim Son, Yongwoo Na, Yongsung Kim, Ji-Hoon Son, Gregory D. Clemenson, Simon T. Schafer, Jong-Yeon Yoo, Sarah L. Parylak, Apua Paquola, Hyunsu Do, et al.

    Metabolic dysregulation of neurons is associated with diverse human brain disorders. Metabolic reprogramming occurs during neuronal differentiation, but it is not fully understood which molecules regulate metabolic changes at the early stages of neurogenesis. In this study, we report that miR-124 is a driver of metabolic change at the initiating stage of human neurogenesis. Proteome analysis has shown the oxidative phosphorylation pathway to be the most significantly altered among the differentially expressed proteins (DEPs) in the immature neurons after the knockdown of miR-124. In agreement with these proteomics results, miR-124-depleted neurons display mitochondrial dysfunctions, such as decreased mitochondrial membrane potential and cellular respiration. Moreover, morphological analyses of mitochondria in early differentiated neurons after miR-124 knockdown result in smaller and less mature shapes. Lastly, we show the potential of identified DEPs as novel metabolic regulators in early neuronal development by validating the effects of GSTK1 on cellular respiration. GSTK1, which is upregulated most significantly in miR-124 knockdown neurons, reduces the oxygen consumption rate of neural cells. Collectively, our data highlight the roles of miR-124 in coordinating metabolic maturation at the early stages of neurogenesis and provide insights into potential metabolic regulators associated with human brain disorders characterized by metabolic dysfunctions.


  • Open Access

    Nobel-winning microRNA, the micromaestro of gene silencing

    by Young-Kook Kim, Jinju Han


  • Open Access

    Author Correction: SLC6A20 transporter: a novel regulator of brain glycine homeostasis and NMDAR function

    by Mihyun Bae, Junyeop Daniel Roh, Youjoung Kim, Seong Soon Kim, Hye Min Han, Esther Yang, Hyojin Kang, Suho Lee, Jin Yong Kim, Ryeonghwa Kang, et al.